Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: A possible role for the coenzyme Q10?

BioFactors

Volumn 23, Issue 1, 2005, Pages 7-14

  Cicero, A F G ^a,c   Derosa, G ^b   Miconi, A ^a   Laghi, L ^a   Nascetti, S ^a   Gaddi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Coenzyme Q10; Fenofibrate; Massive hypertriglyceridemia; Polyunsaturated fatty acids; Therapy

Indexed keywords

C REACTIVE PROTEIN; FENOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; LIPOPROTEIN A; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; UBIDECARENONE; URIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HOMOCYSTINURIA; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 17244371637     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520230102     Document Type: Article

References (34)

1. J.W. Anderson, L.D. Allgood, A. Lawrence, L.A. Altringer, G.R. Jerdack, D.A. Hengehold and J.G. Morel, Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials, Am. J. Clin. Nutr. 71(2) (2000), 472-479.
2. D. Bhatnagar and P.N. Durrington, Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications, Int J Clin Pract 57(4) (2003), 305-314.
3. M.E. Brousseau and E.J. Schaefer, New targets for medical treatment of lipid disorders, Curr. Atheroscler. Rep. 4(5) (2002), 343-349.
4. W.H. Capell, C.A. DeSouza, P. Poirier, M.L. Bell, B.L. Stauffer, K.M. Weil, T.L. Hernandez and R.H. Eckel, Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia, Arterioscler. Thromb. Vasc. Biol. 23(2) (2003), 307-313.
5. W.T. Cefalu, D.J. Schneider, H.E. Carlson, P. Migdal, L.G. Lim, M.P. Izon, A. Kapoor, A. Bell-Farrow, J.G. Terry and B.E. Sobel, Effect of combination glipizide GITS/Metformin on fibrinolytitc and metabolic parameters in poorly controlled type 2 diabetic subjects, Diab. Care. 25(12) (2002), 2123-2128.
6. A.F.G. Cicero, M. Minardi, S. Mirembe, E. Pedro and A. Gaddi, Effects of a new low dose soy protein/β-sitosterol association on plasma lipid levels and oxidation, Eur. J. Nutr. (2004), In press.
7. A.F.G. Cicero, M.P. Panourgia, S. Linarello, S. D'Addato, Z. Sangiorgi and A. Gaddi, Serum lipoprotein(a) levels in a large sample of subjects affected by familial combined hyperlipoproteinemia (FCH) and in general population, J. Cardiovasc. Risk. 10(2) (2003), 149-151.
8. P.E. Cornwell, S.E. Morgan and W.H. Vaughn, Modification of a high-performance liquid chromatograophic method for assay of homocysteine in human plasma, J. Chromatograph. 617 (1993), 136-139.
9. G. de la Serna and C. Cadarso, Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia, Clin. Pharmacol. Ther. 66(2) (1999), 166-172.
10. G. Derosa, A.F.G. Cicero, A. Gaddi, A. Mugellini, E. Ciccarelli and R. Fogari, The effect of L-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus, Clin. Ther. 25(5) (2003), 1429-1439.
11. G. Derosa, A.F.G. Cicero, A. Mugellini, L. Ciccarelli and R. Fogari, Perindopril and candesartan comparative efficacy and safety in type 2 diabetic hypertensive patients, J. Hum. Hypert. 17(6) (2003), 433-435.
12. J. Dierkes, S. Westphal and C. Luley, Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management, Drug. Saf. 26(2) (2003), 81-91.
13. J.C. Fruchart and P. Duriez, HDL and triglyceride as therapeutic targets, Curr. Opin. Lipidol. 13(6) (2002), 605-616.
14. A. Gaddi, A.F.G. Cicero, A. Dormi, V. Pasquarelli and S. D'Addato, The realisation of a project aimed at reducing the plasmatic lipid level in a large Italian rural population improves the mean calcium daily intake: the Brisighella Study, Eur. J. Clin. Nutr. 55(2) (2001), 97-106.
15. A. Gaddi, G.C. Descovich, G. Noseda, C. Fragiacomo, L. Colombo, A. Craveri, G. Montanari and C.R. Sirtori, Controlled evaluation of panthetine, a natural hypolipemic compound, in patients with hyperlipidaemia, Atherosclerosis 50 (1984), 73-83.
16. H.N. Ginsberg, New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism, Circulation 106(16) (2002), 2137-2142.
17. J.M. Hodgson, G.F. Watts, D.A. Playford, V. Burke and K.D. Croft, Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes, Eur. J. Clin. Nutr. 56(11) (2002), 1137-1142.
18. J.E. Hokanson, Hypertriglyceridemia and risk of coronary heart disease, Curr. Cardiol. Rep. 4(6) (2002), 488.
19. C. Hottelart, N. El Esper, F. Rose, J.M. Achard and A. Fournier, Fenofibrate increases creatininemia by increasing metabolic production of creatinine, Nephron 92(3) (2002), 536-541.
20. R.M. Kraus, R.H. Eckel, B. Howerd, L.J. Appel, S.R. Danies, E.J. Deckelbaum, J.W. Jr. Erdman et al., AHA Dietary Guidelines: revision 2000. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association, Circulation 102(18) (2000), 2284-2299.
21. G. Lenaz, R. Fato, C. Castelluccio, M. Battino, M. Cavazzoni, H. Rauchova and G.P. Castelli, Coenzyme Q saturation kinetics of mitochondrial enzymes: Theory, experimental aspects and biomedical implications, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers, T. Yamagami and G.P. Littarru, eds, Elsevier, Amsterdam, 1991, pp. 11-18.
22. M. Mahmoud and P.J. Gaffney, Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA/INH), Thromb. Haemost. 53 (1985), 356-359.
23. H. Munkholm, H.H. Hansen and K. Rasmussen, Coenzyme Q10 treatment in serious heart failure, Biofactors 9(2-4) (1999), 285-289.
24. J. Najib, Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation, Clin. Ther. 24(12) (2002), 2022-2050.
25. G.R. Norman and D.E. Streiner, Biostatistics. The bare essential, 2nd Edition., Hamilton: B.C. Decker Inc, 2000, pp. 139-144.
26. B. Okopien, L. Cwalina, M. Lebek, J. Kowalski, M. Zielinski, M. Wisniewska-Wanat, Z. Kalina and Z.S. Herman, Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia, Int. J. Clin. Pharmacol. Ther. 39(12) (2001), 551-557.
27. R.J. Rapp, Hypertriglyceridemia: a review beyond low-density lipoprotein, Cardiol. Rev. 10(3) (2002), 163-172.
28. W. Roberts, R. Sedrick, L. Moulton, A. Spencer and N. Rifai, Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications, Clin. Chem. 46 (2000), 461-468.
29. R.B. Singh and M.A. Niaz, Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role, Int. J. Cardiol. 68(1) (1999), 23-29.
30. R.B. Singh, M.A. Niaz, S.S. Rastogi, P.K. Shukla and A.S. Thakur, Effect of hydrosoluble coenzyme Q10 on blood pressure and insulin resistance in hypertensive patients with coronary artery disease, J. Hum. Hypertens. 13(3) (1999), 203-208.
31. 2+ precipitation procedure for quantitation of high-density- lipoprotein cholesterol, Clin. Chem. 28 (1982), 1379-1388.
32. G.F. Watts, D.A. Playford, K.D. Croft, N.C. Ward, T.A. Mori and V. Burke, Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus, Diabetologia 45(3) (2002), 420-426.
33. D. Yadav and C.S. Pitchumoni, Issues in hyperlipidemic pancreatitis, J. Clin. Gastroenterol. 36(1) (2003), 54-62.
34. Y. Yamamura, A survey of the therapeutic uses of coenzyme Q. G., in: Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone, G. Lenaz, ed., John Wiley & Sons, New York, 1985, pp. 479-505.